NCT01673438 2022-02-10Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid TumorsImmunityBio, Inc.Phase 1 Completed15 enrolled